Earnings call transcript: Loblaw Q1 2026 beats EPS, misses revenue By Investing.com

Loblaw reported Q1 2026 adjusted EPS of CAD 0.52, slightly above the CAD 0.5173 consensus, while revenue of CAD 14.48B missed the CAD 14.6B forecast. Adjusted EBITDA rose 6% to CAD 1.7B, online sales grew 20.3%, and the dividend was raised 10% for the 15th straight year. Management flagged ongoing inflation and pricing pressure, but reaffirmed confidence in 2026 despite earnings drag from new store and automation investments.

Analysis

The market is treating this as a clean miss, but the more important signal is that the business is reaccelerating in the exact places that defend cycle durability: discount, pharmacy, and digital. That mix shifts Loblaw from a pure inflation beneficiary into a share-gain compounder, which should support multiple expansion only if investors start believing the growth is less macro-dependent and more structural. The catch is that the market already knows this story; the stock’s rebound suggests the first-order selloff was driven by headline revenue optics, not a change in underlying earnings power.

The second-order effect is margin normalization could be more resilient than the revenue line implies. If discount penetration keeps rising while construction costs have already come down materially, Loblaw can keep opening units in smaller catchments without destroying returns; that is a meaningful operating leverage story over 12-24 months. The flip side is that the new-store and automation spend still suppress near-term EPS, so the setup works only if traffic remains steady enough to absorb the investment drag before competitive pricing resets margins.

The underappreciated risk is not consumer weakness; it is mix volatility in pharmacy and the potential for category compression if generic GLP-1 access broadens faster than reimbursement/volume offsets can compensate. That could create a near-term top-line headwind even as it helps affordability and traffic, making quarterly reads noisy. The overvalued flag matters here: at this point, the stock is less a fundamental short than a valuation duration trade vulnerable to any sign that same-store gains are plateauing or that the cost base is not translating into faster EPS inflection.

Key Decisions for Investors

• Stay long L.TO, but only as a 3-6 month hold and trim into strength: the risk/reward is better on pullbacks than on chasing the post-earnings bounce, given valuation is already stretched.
• Pair trade: long L.TO / short Canadian food retail or defensive consumer peers with weaker discount leverage over the next 1-2 quarters; Loblaw’s mix shift and unit economics should keep relative fundamentals superior even if the sector de-rates.
• If available, buy 3-6 month L.TO puts or put spreads into the next earnings cycle to hedge valuation risk; the catalyst is not demand collapse, but any evidence that pharmacy mix or GLP-1 dynamics dilute margin faster than expected.
• Watch EQB.TO tactically around the PC Financial close and proceeds deployment: the cash release is a buyback-supportive catalyst, but the stock can overshoot if the market assumes immediate EPS accretion that won’t fully land until 2027.
• For mean-reversion traders, fade any rally that prices in perpetual mid-single-digit top-line growth; the setup is durable, but the path to upside likely comes from execution and capital returns, not multiple expansion.